Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

AZD5863

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca, Harbour BioMed

Drug class:

CD3 agonist, CLDN18.2 inhibitor

Related drugs:

‹

TAC101-Claudin18.2 (0)

blinatumomab (52)

epcoritamab-bysp (11)

elranatamab-bcmm (8)

mosunetuzumab-axgb (2)

talquetamab-tgvs (2)

teclistamab-cqyv (2)

glofitamab-gxbm (1)

JNJ-63898081 (1)

ABBV-383 IV (0)

CD30 biAb-AATC (0)

JNJ-63709178 (0)

JNJ-67571244 (0)

PF-06671008 (0)

PF-07062119 (0)

PF-07260437 (0)

catumaxomab (0)

UMG2-CD3 BTCE (0)

Undisclosed HER2Bi-armed ATC (0)

activated CIK and bispecific antibody (0)

activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)

huCD33-BsAb (0)

zolbetuximab (11)

TAC101-Claudin18.2 (0)

›

CLDN18.2 expression	Esophageal Cancer	CLDN18.2 expression	Esophageal Cancer	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2